Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib + Obinutuzumab + Venetoclax in R/R BV-MCL
NCT06324994Phase 2Not yet recruiting
- Sponsor
- Dalian Medical University
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linperlisib in mantle cell lymphoma (MCL), sponsored by Dalian Medical University. Planned start May 2024; status: not yet recruiting.
02
Drugs
linperlisib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06324994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324994.